Companies: 10,795·Total market cap: $144.5T
CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSPNASDAQHealthcare● Active
$51.76
$-0.08(-0.15%)
Market Cap$5.0B
P/E Ratio
52W High$78.48
52W Low$37.02

CRISPR Therapeutics AG (CRSP) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

crsp · stock forecast · 38 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 38 Wall Street analysts in the past 3 months

SellBuy

Buy

38 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
22
Hold
14
Sell
2
Strong Sell
0
Total: 38 · Buy rate: 57.9%

12-Month Price Target

High

$82.00

Consensus

$64.60

+24.6% upside

Low

$33.00

Median: $76 · Last Close: $51.84

The CRISPR Therapeutics AG (CRSP) analyst consensus is Buy, based on ratings from 38 Wall Street analysts over the past 3 months. The average 12-month CRSP price target is $64.60, representing +24.6% upside from the current price of $51.84.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $65 (24.6%)

Consensus Target

$64.60

24.6% upside

High Target

$82

58.2%

Low Target

$33

-36.3%

Current Price

$51.84

as of today

Based on analyst price targets, the CRSP stock price prediction for the next 12 months ranges from $33 to $82. The consensus CRSP price forecast of $64.60 implies 24.6% upside from the current price of $51.84.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$52.681.61%

1-day model range: $52.3–$53.05. Peak: $53.05 (+1.61%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$36-30.6%
2028$29-43.4%
2029$26-49.6%
2030$24-52.9%
2031-54.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%7%86%
1Buy
1Neutral
12Sell
RSI (14)57.0Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · CRSP · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$53.42SELL
MA 10$53.51SELL
MA 20$52.15SELL
MA 50$52.14SELL
MA 100$52.49SELL
MA 200$55.61SELL
Current $CRSP · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$53.48SELL
EMA 10$53.18SELL
EMA 20$52.72SELL
EMA 50$52.47SELL
EMA 100$52.92SELL
EMA 200$53.13SELL
Current $CRSP · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Bernstein2026-05-13
Maintains
Market PerformMarket Perform
Citigroup2026-05-06
Maintains
BuyBuy
Piper Sandler2026-03-17
Maintains
OverweightOverweight
Chardan Capital2026-02-17
Maintains
BuyBuy
TD Cowen2026-02-13
Maintains
HoldHold
Evercore ISI Group2026-02-13
Maintains
OutperformOutperform
Needham2026-02-13
Maintains
BuyBuy
Citizens2026-01-30
Maintains
Market OutperformMarket Outperform
Citizens2025-12-23
Maintains
Market OutperformMarket Outperform
Needham2025-12-23
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on CRISPR Therapeutics AG (CRSP) stock. Of the recent 225 rating actions, 7 were upgrades and 9 were downgrades. 38 analysts currently cover CRSP.

Analyst Recommendation Trends

Buy ratings312
Hold ratings211
Sell ratings00

CRSP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$40M

↓ 93.2% YoY

Revenue Next Year

$138M

↑ 247.8% YoY

EPS This Year

$-4.87

EPS Next Year

$-3.62

↓ 25.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CRSP EPS of $-4.87 for the current fiscal year, based on estimates from 17 analysts. The CRSP revenue forecast is $40M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CRSP stock forecast is supported by two independent data sources: analyst consensus ratings from 38 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRSP price target is $64.60 (+24.6% upside), with an analyst consensus of Buy.

The CRSP short-term stock prediction for tomorrow is $52.68 (+1.61%). The CRSP stock price prediction for 2027 estimates an average of $36. The CRSP stock prediction for 2030 projects a range of $23–$26.

CRISPR Therapeutics AG trades on NASDAQ under the ticker CRSP. The CRSP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 58% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

CRSP forecast · 8 questions

According to 38 Wall Street analysts, the average 12-month CRSP price target is $64.60, with a high forecast of $82.00 and a low of $33.00. The median price target is shown in the chart above when available. This implies +24.6% potential upside from the current price of $51.84.

CRSP price targetWhat is CRSP price targetCRSP analyst price targetCRSP 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.